Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7907302 | 1.00 | HPGD (0.44) | HPGDSMN1; SMN2GLAGAACYP2C9 | |
| SCHEMBL7910505 | 0.96 | HPGD (0.42) | HPGDSMN1; SMN2GLAGAACYP2C9 | |
| SCHEMBL7910502 | 0.96 | HPGD (0.42) | HPGDSMN1; SMN2GLAGAACYP2C9 | |
| SCHEMBL7910499 | 0.96 | HPGD (0.42) | HPGDSMN1; SMN2GLAGAACYP2C9 | |
| SCHEMBL12730609 | 0.95 | HPGD (0.41) | HPGDSMN1; SMN2GLAGAACYP2C9 | |
| SCHEMBL9406597 | 0.95 | CYP2C9 (0.40) | HPGDSMN1; SMN2GAACYP2C9MEN1 | |
| SCHEMBL9406600 | 0.95 | CYP2C9 (0.40) | HPGDSMN1; SMN2GAACYP2C9MEN1 | |
| SCHEMBL12031981 | 0.92 | HPGD (0.40) | HPGDSMN1; SMN2GLAGAACYP2C9 | |
| SCHEMBL9405776 | 0.92 | HPGD (0.38) | HPGDSMN1; SMN2GAACYP2C9MEN1 | |
| SCHEMBL9405772 | 0.92 | HPGD (0.38) | HPGDSMN1; SMN2GAACYP2C9MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5248447-A | 2,3-difluorohydroquinone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-09-28 | — | — | US | claimed |
| US-10519377-B1 | Liquid crystal composition of negative monomer containing cyclopentyl cyclohexenyl and liquid crystal display element or liquid crystal display thereof | Shijiazhuang Chengzhi Yonghua Display Material Co., Ltd (CN) | 2019-12-31 | — | — | US | disclosed |
| US-9517990-B2 | Negative dielectric anisotropic liquid crystal compounds containing 2,3-difluorophenyl group, and preparation method and use thereof | Shijiazhuang Chenzhi Yonghua Display Materials Co., Ltd. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-9517990-B2 | Negative dielectric anisotropic liquid crystal compounds containing 2,3-difluorophenyl group, and preparation method and use thereof | Shijiazhuang Chenzhi Yonghua Display Materials Co., Ltd. (CN) | 2016-12-13 | — | — | US | disclosed |
| US-20150152330-A1 | Negative Dielectric Anisotropic Liquid Crystal Compounds Containing 2,3-Difluorophenyl Group, and Preparation Method and Use Thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| US-20150152330-A1 | Negative Dielectric Anisotropic Liquid Crystal Compounds Containing 2,3-Difluorophenyl Group, and Preparation Method and Use Thereof | SHIJIAZHUANG CHENGZHI YONGHUA DISPLAY MATERIALS CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| US-7718232-B2 | Nematic liquid crystal composition and liquid crystal display element that used the composition | DAINIPPON INK & CHEMICAL, INC. (JP) | 2010-05-18 | — | — | US | disclosed |
| US-20080149889-A1 | Nematic Liquid Crystal Composition and Liquid Crystal Display Element That Used the Composition | DAINIPPON INK AND CHEMICALS, INC. (JP) | 2008-06-26 | — | — | US | disclosed |
| US-6210760-B1 | SHORT SWITCHING TIMES AND GRADIENTS AND ANGULAR DEPENDENCIES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2001-04-03 | — | — | US | disclosed |
| US-5876626-A | HIGH SPEED SWITCHING | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1999-03-02 | — | — | US | disclosed |
| US-5387369-A | With specified mixture of components; short switching times | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-02-07 | — | — | US | disclosed |
| US-5279764-A | Dihalogenobenzene derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1994-01-18 | — | — | US | disclosed |
| US-5248447-A | 2,3-difluorohydroquinone derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1993-09-28 | — | — | US | disclosed |
| US-5188758-A | Electrooptical display element using a supertwist liquid crystal having specified elastic constants | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1993-02-23 | — | — | US | disclosed |
| US-5178790-A | With excellent steepness of characteristics | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 1993-01-12 | — | — | US | disclosed |
| US-5143642-A | Thiadiazoles | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1992-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152330-A1 | Negative Dielectric Anisotropic Liquid Crystal Compounds Containing 2,3-Difluorophenyl Group, and Preparation Method and Use Thereof | CTNND1, YWHAZ, DVL1 | HPGD 4458/4885SMN1; SMN2 4766/4885GLA 943/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.